Taiho Oncology, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2002-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.taihooncology.com
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 361
- Registration Number
- NCT01285557
A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2008-09-22
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Registration Number
- NCT00756782
Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT00687596
- Locations
- 🇮🇹
I.R.C.C.S. San Matteo University Hospital, Golgi, Pavia, Italy
Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2008-04-28
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT00667628
- Locations
- 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵National hospital organization Shikoku Cancer Center, Matsuyama, Ehime, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan
Phase 2 Study of S-1 in Advanced or Metastatic Pancreatic Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT00651742
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00652054
Phase 2 Study of S-1 in Combination With Cisplatin as 1st Line Therapy in Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00651833
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 57
- Registration Number
- NCT00652561
A Safety and Efficacy Study in Patients With Gastric Cancer
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 1053
- Registration Number
- NCT00400179
- Locations
- 🇺🇸
Saint Joseph Medical Center, Burbank, California, United States
🇺🇸Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
- First Posted Date
- 2006-11-16
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00400023
- Locations
- 🇺🇸
Premiere Oncology, A Medical Corporation, Santa Monica, California, United States
🇺🇸Premiere Oncology of Arizona, Scottsdale, Arizona, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
© Copyright 2024. All Rights Reserved by MedPath